Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Weinberger MH, et al.
American Journal of Hypertension, 15(8), 709-716 (2002)
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects: insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy
Rossignol P, et al.
Journal of the American College of Cardiology, 58(19), 1958-1966 (2011)
Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series
Journal of steroid biochemistry, 32(1B), 223-227 (1989-01-01)
The use of spironolactone in the treatment of hypertension has been limited by the occurrence of sexual side effects, mainly menstrual disturbances in women and gynaecomastia in men. In order to minimize this limitation on the use of an effective
The retention performance of mice in a passive-avoidance task was facilitated by low doses (0.3 mg/kg) of the competitive NMDA-receptor blocker CGP 37849, but impaired by high doses (30 mg/kg). The facilitatory effect was selectively suppressed by elevation of the
